(Q83390306)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Dietmar W Siemann

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

David J Chaplin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Patricia A Walicke

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

189-197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma

22 January 2020

cites work

1 reference

12 December 2020

In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation.

1 reference

12 December 2020

Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.

1 reference

12 December 2020

Differentiation and definition of vascular-targeted therapies.

1 reference

12 December 2020

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate

1 reference

12 December 2020

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

1 reference

12 December 2020

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

12 December 2020

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

12 December 2020

Vascular-targeting therapies for treatment of malignant disease.

1 reference

12 December 2020

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

1 reference

12 December 2020

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

1 reference

12 December 2020

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.

1 reference

12 December 2020

Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study

1 reference

12 December 2020

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

12 December 2020

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status

1 reference

12 December 2020

Tumour vasculature as a target for cancer therapy.

1 reference

12 December 2020

An update on the clinical development of drugs to disable tumor vasculature

1 reference

12 December 2020

Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

1 reference

12 December 2020

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

1 reference

12 December 2020

Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy

1 reference

12 December 2020

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

1 reference

12 December 2020

Phase I trial of combretastatin a-4 phosphate with carboplatin

1 reference

12 December 2020

Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications

1 reference

12 December 2020

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

1 reference

12 December 2020

Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate

1 reference

12 December 2020

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature

1 reference

12 December 2020

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence

1 reference

12 December 2020

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy

1 reference

12 December 2020

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

1 reference

12 December 2020

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

1 reference

12 December 2020

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

12 December 2020

Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs

1 reference

12 December 2020

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma

1 reference

12 December 2020

The development of combretastatin A4 phosphate as a vascular targeting agent

1 reference

12 December 2020

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

1 reference

12 December 2020

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy

1 reference

12 December 2020

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors

1 reference

12 December 2020

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

1 reference

12 December 2020

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

12 December 2020

The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies

1 reference

12 December 2020

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

1 reference

12 December 2020

10.1517/13543780802691068

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19236265%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference